 SAN DIEGO, March 10, 2021 PRNewswire -- Mirati Therapeutics, Inc. NASDAQ: MRTX, a late-stage targeted oncology company, today announced it will present initial preclinical data on the Companys synthetic lethal PRMT5 inhibitor during a late-breaking minisymposium at the American Association for Cancer Research AACR Virtual Annual Meeting taking place April 10-15, 2021. At Mirati, we are applying leading-edge drug discovery strategies, such as synthetic lethality, to translate this exciting research approach into meaningful, targeted therapeutic options for patients with cancer, said James Christensen, Ph.D. 